Good MorningEquities ended the month of November on solid footing boosted by remarks by Fed chief Jerome Powell. Mr. Powell signaled the FOMC may shift its stance as soon as the next meeting and slow the pace of interest rate hikes. While the market cheered the news the takeaway is that inflation is still running hot and underpinned by rising wages. In this light, the pace of hikes may have slowed but it is not going to end any sooner than previously indicated. The risk now is that inflation will only subside moderately and prolong the time it takes for the FOMC to do its job.
Today's news may alter the entire FOMC outlook once again so don't be surprised if the market makes an about face. The PCE price index is expected to cool from the previous month but may not have cooled as much as expected. Regardless, the index is expected to support the current outlook for interest rate hikes which is having a negative impact on the outlook for S&P 500 earnings. While this dynamic is overshadowing the market no rally should be trusted. Featured: The election is close. Your report is free. (Ad) 
|
Consumer Discretionary | |
China-based electric vehicle maker NIO (NYSE: NIO) powered more than 19% higher Wednesday. Shares were trading at $12.51 with an hour left in the session.
NIO, along with other Chinese EV manufacturers, rose in tandem with XPeng (NYSE: XPEV), which reported a third-quarter loss of $0.36, meeting... Read the Full Story |
|
From Our Partners | | A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions.
A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer.
Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider. | | Click here to see the document and learn protective steps |
|
Markets | | Updated: Federal Reserve Chairman Jerome Powell confirmed Wednesday, Nov 30, that smaller interest rate increases are likely ahead even as he sees progress in the fight against inflation as largely inadequate.We are approaching that time of year when the stock market gets into a holiday mood trigger... Read the Full Story |
|
Healthcare | |
Shares of Cosmos Holdings (NASDAQ: COSM) stock are up 618% in November. This penny stock has gone from trading for actual pennies per share to 68 cents per share at the time of this writing. The company has had some favorable news to report. But this has all the earmarks of a short squeeze.
Pric... Read the Full Story |
|
From Our Partners | | One fund holds Nvidia, CrowdStrike, Palantir and other major AI names, and pays a 34% annualized distribution rate.
Instead of guessing which AI stock wins, this fund delivers income every single Thursday, up to $1,051 a month.
Chief Income Strategist Tim Plaehn breaks down what's inside the fund and how the weekly payouts work. | | Watch the free video to see how the weekly payouts work |
|
Technology | |
Results from Crowdstrike (NASDAQ: CRWD) and NetApp (NASDAQ: NTAP) have brought dark clouds to the cloud-stock universe. While both companies had good CQ3 periods the outlook for the rest of the year is gloomy indeed. The news has both stocks down double digits but this may be an opportunity. Analy... Read the Full Story |
|
Consumer Staples | |
In what has been a tough year for growth investors, few equity categories have provided the spark counted on for portfolio appreciation. The energy sector is one, but it's a sea of red almost everywhere else.
This means two things: 1) many brokerage accounts will be limping into 2023 with lower v... Read the Full Story |
|
From Our Partners | | Every Monday afternoon, we send out a stock trade idea to some of MarketBeat's best and most valued subscribers. We think you are one of those people...but you are not on our alert distribution list yet. This once a week alert is sent out via SMS so that you can see it right away. Last week's alert was very popular with our subscribers, you won't want to miss out on the next alert -- and it doesn't cost you a thing. We're going to send out another trade idea on Monday around noon, and I want to make sure that you're able to see it. | | Add your name to the distribution list here |
|
Consumer Staples | |
For those who’ve balked at Hormel’s (NYSE: HRL) high valuation the time to buy may be at hand. The company’s FQ4 results were weak and came with weak guidance that has this Dividend Aristocrat down at the lowest levels in weeks and trading near the 2022 lows. While the earnings r... Read the Full Story |
|
Healthcare | |
Axsome Therapeutics, Inc. (NASDAQ: AXSM) stock got a major boost in the final days of November after posting positive results from recent clinical trials. The phase-3 study saw the new Alzheimer's Disease agitation treatment, known for now as AXS-05, meet not only its primary endpoint but also key... Read the Full Story |
|
Technology | |
Despite worries that higher inflation and lower consumer sentiment would slow Black Friday sales, companies such as Apple (NASDAQ: AAPL), Microsoft (NASDAQ: MSFT) and Sony Group (NYSE: SONY) notched strong sales.
Although consumers are tightening their belts as prices for food, fuel, and other b... Read the Full Story |
|
Healthcare | |
Investing in pot stock has been one wild ride for Organigram (NASDAQ: OGI). The industry got off to a rip-roaring start, saw its value increase meteorically, and then slowly faded away as the hopes and dreams of cannabis profits slipped away. Now, roughly 4 years since the legalization of adult-us... Read the Full Story |
|
Markets | |
Hibbett Sports (NASDAQ: HIBB) reported a strong Q3 but strength is in the eye of the beholder. The company’s robust growth and outlook for the year is strong for investors but not so much for the analysts who had been expecting so much more. The takeaway is that strength in the market is ebb... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia. | | View Today's Stock Pick |
|
